Disc Medicine (IRON) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-129.7M
Net Income
-109.4M
Balance Sheet Metrics
Total Assets
496.8M
Total Liabilities
53.2M
Shareholders Equity
443.6M
Debt to Equity
0.12
Cash Flow Metrics
Operating Cash Flow
-95.3M
Free Cash Flow
-94.4M
Revenue & Profitability Trend
Disc Medicine Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 129.7M | 91.1M | 47.5M | 30.9M | 34.0M |
| Operating Income | -129.7M | -91.1M | -47.5M | -30.9M | -34.0M |
| Pre-tax Income | -109.0M | -76.3M | -46.8M | -36.0M | -40.8M |
| Income Tax | 355.0K | 99.0K | 0 | - | - |
| Net Income | -109.4M | -76.4M | -46.8M | -36.0M | -40.8M |
| EPS (Diluted) | - | -$3.42 | -$45.05 | -$44.90 | -$9.01 |
Income Statement Trend
Disc Medicine Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 493.6M | 365.7M | 198.5M | 90.5M | 5.1M |
| Non-Current Assets | 3.2M | 2.3M | 1.7M | 1.9M | 3.3M |
| Total Assets | 496.8M | 368.0M | 200.2M | 92.4M | 8.3M |
| Liabilities | |||||
| Current Liabilities | 23.3M | 21.4M | 22.6M | 13.4M | 24.9M |
| Non-Current Liabilities | 29.9M | 1.4M | 1.0M | 143.2M | 5.3M |
| Total Liabilities | 53.2M | 22.9M | 23.6M | 156.6M | 30.2M |
| Equity | |||||
| Total Shareholders Equity | 443.6M | 345.1M | 176.6M | -64.2M | -21.9M |
Balance Sheet Composition
Disc Medicine Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -109.4M | -76.4M | -46.8M | -36.0M | -40.8M |
| Operating Cash Flow | -95.3M | -74.3M | -44.2M | -31.4M | -36.8M |
| Investing Activities | |||||
| Capital Expenditures | -505.0K | -89.0K | -151.0K | -68.0K | -22.0K |
| Investing Cash Flow | -292.3M | -89.0K | -151.0K | -68.0K | -22.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 214.9M | 199.1M | 148.8M | 281.2M | 34.1M |
| Free Cash Flow | -94.4M | -73.6M | -42.4M | -27.6M | -32.7M |
Cash Flow Trend
Disc Medicine Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
4.99
Forward P/E
-9.81
Price to Book
2.70
PEG Ratio
-9.81
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-23.34%
Return on Assets
-16.25%
Financial Health
Current Ratio
37.65
Debt to Equity
4.64
Beta
2.50
Per Share Data
EPS (TTM)
-$3.89
Book Value per Share
$19.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| iron | 1.8B | 4.99 | 2.70 | -23.34% | 0.00% | 4.64 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.